An individualized gene expression signature for prediction of lung adenocarcinoma metastases

Our laboratory previously reported an individual‐level signature consisting of nine gene pairs, named 9‐GPS. This signature was developed by training on microarray expression data and validated using three independent integrated microarray data sets, with samples of stage I non‐small‐cell lung cancer after complete surgical resection. In this study, we first validated the cross‐platform robustness of 9‐GPS by demonstrating that 9‐GPS could significantly stratify the overall survival of 213 stage I lung adenocarcinoma (LUAD) patients detected with RNA‐sequencing platform in The Cancer Genome Atlas (TCGA; log‐rank P = 0.0318, C‐index = 0.55). Applying 9‐GPS to all the 423 stage I‐IV LUAD samples in TCGA, the predicted high‐risk samples were significantly enriched with clinically diagnosed metastatic samples (Fisher's exact test, P = 0.0015). We further modified the voting rule of 9‐GPS and found that the modified 9‐GPS had a better performance in predicting metastasis states (Fisher's exact test, P < 0.0001). With the aid of the modified 9‐GPS for reclassifying the metastasis states of patients with LUAD, the reclassified metastatic samples presented clearer transcriptional and genomic characteristics compared to the reclassified nonmetastatic samples. Finally, regulator network analysis identified TP53 and IRF1 with frequent genomic aberrations in the reclassified metastatic samples, indicating their key roles in driving tumor metastasis. In conclusion, 9‐GPS is a robust signature for identifying early‐stage LUAD patients with potential occult metastasis. This occult metastasis prediction was associated with clear transcriptional and genomic characteristics as well as the clinical diagnoses.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[3]  A. Marchetti,et al.  p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.

[4]  P. Kleihues,et al.  p53 mutations in primary human lung tumors and their metastases , 1994, Molecular carcinogenesis.

[5]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[6]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[7]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[8]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[9]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[10]  H. Koeffler,et al.  Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. , 2001, Cancer research.

[11]  F. Hirsch,et al.  The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. , 2002, Lung cancer.

[12]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[13]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[14]  R. Kerbel,et al.  Versican/PG‐M G3 domain promotes tumor growth and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Douglas G Altman,et al.  The logrank test , 2004, BMJ : British Medical Journal.

[16]  M. Tada,et al.  Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. , 2004, The Journal of surgical research.

[17]  James Lyons-Weiler,et al.  Prediction of Lymph Node Metastasis by Analysis of Gene Expression Profiles in Primary Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[18]  Ju Han Kim,et al.  The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer , 2006, Journal of Thoracic Oncology.

[19]  F. Buttitta,et al.  Alterations in Non-Small Cell Lung Cancers Correlate with Metastatic Involvement of Hilar and Mediastinal Lymph Nodes 1 , 2006 .

[20]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[21]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[22]  N. Kohl,et al.  Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. , 2007, Cancer research.

[23]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[24]  Myung-Shik Lee,et al.  Metastasis-associated protein 1 inhibits p53-induced apoptosis. , 2007, Oncology reports.

[25]  Nam Huh,et al.  Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression , 2008, Clinical Cancer Research.

[26]  Andrew B. Nobel,et al.  Merging two gene-expression studies via cross-platform normalization , 2008, Bioinform..

[27]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[28]  John J. Crowley,et al.  国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[29]  Charles M Perou,et al.  A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. , 2009, Cancer research.

[30]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[31]  David M. Simcha,et al.  Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.

[32]  L. Sequist,et al.  EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. , 2010, Neuro-oncology.

[33]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[35]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[36]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[37]  Johan Staaf,et al.  Relation between smoking history and gene expression profiles in lung adenocarcinomas , 2012, BMC Medical Genomics.

[38]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[39]  F. Lallemand,et al.  Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. , 2011, Journal of the National Cancer Institute.

[40]  K. Coombes,et al.  Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Non–Small-Cell Lung Cancer Patients , 2011, Clinical Cancer Research.

[41]  Dung-Tsa Chen,et al.  Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. , 2011, Journal of the National Cancer Institute.

[42]  Ron Shamir,et al.  SPIKE: a database of highly curated human signaling pathways , 2010, Nucleic Acids Res..

[43]  Jing Zhu,et al.  GO-function: deriving biologically relevant functions from statistically significant functions , 2012, Briefings Bioinform..

[44]  Mats Lambe,et al.  Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation , 2012, Clinical Cancer Research.

[45]  A. Nicholson,et al.  Impact of collection and storage of lung tumor tissue on whole genome expression profiling. , 2012, The Journal of molecular diagnostics : JMD.

[46]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[47]  E. Petricoin,et al.  -Omics and Cancer Biomarkers: Link to the Biological Truth or Bear the Consequences , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[48]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[49]  Illés J. Farkas,et al.  SignaLink 2 – a signaling pathway resource with multi-layered regulatory networks , 2013, BMC Systems Biology.

[50]  Matthew D. Wilkerson,et al.  Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation , 2012, PloS one.

[51]  Satoru Miyano,et al.  Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. , 2012, Cancer research.

[52]  Hugues Bersini,et al.  Batch effect removal methods for microarray gene expression data integration: a survey , 2013, Briefings Bioinform..

[53]  D. Nguyen,et al.  EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. , 2013, Cancer research.

[54]  James J. Chen,et al.  Identification of reproducible gene expression signatures in lung adenocarcinoma , 2013, BMC Bioinformatics.

[55]  D. Yee,et al.  Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis , 2013, PloS one.

[56]  J S Liu,et al.  Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity , 2013, British Journal of Cancer.

[57]  Igor Jurisica,et al.  Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[58]  C. Zheng,et al.  Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer. , 2015, International journal of clinical and experimental pathology.

[59]  M. Roudbaraki,et al.  CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis , 2015, Oncogene.

[60]  C. Sander,et al.  Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014, Genome Biology.

[61]  Johan Staaf,et al.  Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma , 2015, Clinical Cancer Research.

[62]  Qiang Sun,et al.  The influence of cancer tissue sampling on the identification of cancer characteristics , 2015, Scientific Reports.

[63]  Zheying Zhang,et al.  IFN-γ-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1. , 2015, Cancer letters.

[64]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[65]  Qiang Sun,et al.  Individual-level analysis of differential expression of genes and pathways for personalized medicine , 2015, Bioinform..

[66]  Zheng Guo,et al.  Differential expression analysis for individual cancer samples based on robust within-sample relative gene expression orderings across multiple profiling platforms , 2016, Oncotarget.

[67]  Libin Chen,et al.  Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer , 2016, Briefings Bioinform..

[68]  Zheng Guo,et al.  Identifying Reproducible Molecular Biomarkers for Gastric Cancer Metastasis with the Aid of Recurrence Information , 2016, Scientific Reports.

[69]  F. Wei,et al.  Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. , 2016, Cancer research.

[70]  Na Li,et al.  Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples , 2016, Oncotarget.